Search:

Type: Posts; User: gpawelski; Keyword(s):

Search: Search took 0.00 seconds.

  1. Is It Ethical to Deny Cancer Patients Functional Analyses?

    Robert A. Nagourney, M.D.

    The ethical standards that govern human experimentation have become an important topic of discussion. Clinical trials are conducted to resolve medical questions while...
  2. Scientists challenge the genetic interpretation of biology

    A proposal for reformulating the foundations of biology, based on the 2nd law of thermodynamics and which is in sharp contrast to the prevailing genetic view, is published in the Journal of the Royal...
  3. Pharmacogenomics can be defined as the study of...

    Pharmacogenomics can be defined as the study of how a person’s genetic makeup determines response to a drug. Although any number of labs and techniques can detect mutant genes, this area of...
  4. First FDA Authorization for Next-Generation Sequencer

    Francis S. Collins, M.D., Ph.D., and Margaret A. Hamburg, M.D.
    N Engl J Med 2013; 369:2369-2371December 19, 2013DOI: 10.1056/NEJMp1314561

    Article

    This year marks 60 years since James Watson...
  5. Genome-wide sequencing in cancer: not ready for prime time

    (Reuters Health) - Routine genome-wide screening of cancers is likely a long way off, a new paper says.

    The technology, known as next-generation sequencing, promises to revolutionize doctors'...
  6. Debating Next-Generation Deep Sequencing

    At ESMO, experts assess the clinical use of genome sequencing

    Vienna—Should oncologists begin using deep genome sequencing in their clinical practice? Next-generation sequencing (NGS) technologies...
  7. Is Genomic Sequencing Ready for Prime Time in Drug Selection?

    Next-generation sequencing (NGS) technologies have come a long way since 1977 when Frederick Sanger developed chain-termination sequencing, but are they ready for prime time in drug selection?
    ...
  8. There is the issue about cell-lines vs fresh...

    There is the issue about cell-lines vs fresh cells. Cell-lines have always played, and continue to play, an important role in drug screening and drug development.

    The problem is that cell-lines do...
  9. Venture Capital Goes Genomic

    Robert A. Nagourney, M.D.

    During the 1960s, 70s and into the 90s, a field of investigation arose that examined buyer’s practices when it came to the consumption of goods and services. Algorithms...
  10. Accuracy and Clinical Utility of In Vitro Cytometric Profiling

    Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis.

    Sub-category: Molecular Diagnostics and...
  11. Targetable genetic alterations detected by next-generation sequencing

    Needle biopsies assay on 33 pretherapy primaries and 17 mBCs. NGS of 3,230 exons in 182 cancer-related genes and 37 introns in 14 genes. 117 "potentially" targetable driver mutations were identified...
  12. Gene Sequencing for Drug Selection?

    Researchers have realized that cancer biology is driven by signaling pathways. Cells speak to each other and the messages they send are interpreted via intracellular pathways known as signal...
  13. Foundation Medicine and the Big Barrier to Cancer Genomic Sequencing

    According to Dr. Eric Topol, Director, Scripps Translational Science Institute, recent studies have highlighted the potential value of whole genome or exome sequencing to precisely guide therapy for...
Results 1 to 13 of 13


BTC Inc's Disclaimer and Privacy Policy

The material on this site is for information & support purposes only, and is not a substitute for medical advice provided by a licensed health care provider. Always consult your doctor before trying anything that you find online.